← Back to patent-cliff list
Motixafortide
Tier C — Watch / tradeMotixafortide
Biokine
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CXCR4
Brand：APHEXDA
Indications (approved)：Multiple myeloma, Haematopoietic stem cell transplantation
Regional status
US
Approved
2023-09-08
EU
Phase III
2018-03-23
China
Phase III
2025-12-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Motixafortide?
Approved indications include: Multiple myeloma, Haematopoietic stem cell transplantation.
When does the Motixafortide patent expire?
No public expiry year is available for Motixafortide yet; this page updates once verified.
How do I get a quote for Motixafortide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01